Exome

CancerXOME™-R

CancerXOME™-R captures and analyzes the coding regions of >20,000 genes. Both tumor and normal samples are requested and prepared using proprietary methods that accommodate low abundance, poor quality sample DNA. Samples are sequenced at high coverage to identify tumor-specific (somatic) mutations, microsatellite instability (MSI) and copy number changes.

CancerXOME™-R Key Metrics
Regions AnalyzedCoding regions of >20,000 genes
Sequencing MethodIllumina next generation sequencing
BioinformaticsProprietary methods and visual inspection
Assay Sensitivity>95%
Assay Specificity99.99999%
Sequencing Coverage150x
Turn-around Time6 weeks (rush available)
Sample RequirementsTumor only or tumor and matched normal*
(optimal results)
Sample TypesFrozen tumor, FFPE, cell lines,
blood, saliva, and xenograft
DNA Input Required1 µg (minimum 50 ng)
*For maximum ability to differentiate somatic mutations from germline mutations, tumor and matched normal samples are recommended.
Exome

ImmunoSELECT™-R

Neoantigens are a class of immunogens based on the personal, exquisitely tumor-specific mutations found uniquely in each tumor. Combining PGDx’s highly accurate cancer exome analyses (CancerXOME™-R ) with in silico neoantigen prediction, ImmunoSELECT™-R identifies and prioritizes the most relevant mutation-derived neoantigens.

ImmunoSELECT™-R Key Metrics*
Regions AnalyzedCoding regions of >20,000 genes
Sequencing MethodIllumina next generation sequencing
BioinformaticsProprietary methods and visual inspection
Assay Sensitivity>95%
Assay Specificity>99.99%
Sequencing Coverage150x
Turn-around Time6 weeks (rush available)
Sample RequirementsTumor only or tumor and matched normal**
(optimal results)
Sample TypesFrozen tumor, FFPE, cell lines,
blood, saliva, and xenograft
DNA Input Required1 µg (minimum 50 ng)
*ImmunoSELECT™-R leverages our CancerXOME™-R which offers unsurpassed accuracy with the key performance metrics indicated above.

**For maximum ability to differentiate somatic mutations from germline mutations, tumor and matched normal samples are recommended.
Targeted

CancerSELECT™-R 125

CancerSELECT™-R 125 analyzes the regions of a targeted panel of 125 well-characterized cancer genes. Matched tumor/normal or tumor samples are prepared using proprietary methods that accommodate low abundance, poor quality sample DNA. Combined with a proprietary capture design and high coverage next-generation sequencing, tumor-specific (somatic) mutations, copy number variations, microsatellite instability (MSI) and translocations are identified with a high sensitivity and specificity.

CancerSELECT™-R 125 Key Metrics
Regions AnalyzedCoding regions of 117 genes and
selected regions of 41 genes
Sequencing MethodIllumina next generation sequencing
BioinformaticsPatented PARE, Digital Karyotyping
and VariantDx
Assay Sensitivity>99%
Assay Specificity>99.9999%
Sequencing Coverage1,250x
Turn-around Time2-3 weeks
Sample RequirementsTumor only or tumor and matched normal*
(optimal results)
Sample TypesFrozen tumor, FFPE, cell lines,
blood, saliva, and xenograft
DNA Input Required1 µg (minimum 50 ng)
*For maximum ability to differentiate somatic mutations from germline mutations, tumor and matched normal samples are recommended.